

# Sonia Fabris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7822833/publications.pdf>

Version: 2024-02-01

92  
papers

3,561  
citations

101384

36  
h-index

143772

57  
g-index

92  
all docs

92  
docs citations

92  
times ranked

4994  
citing authors

#	ARTICLE	IF	CITATIONS
1	Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. <i>Haematologica</i> , 2012, 97, 1272-1277.	1.7	254
2	Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. <i>Blood</i> , 2009, 114, e20-e26.	0.6	224
3	A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 603-614.	1.5	134
4	Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations. <i>Journal of Clinical Oncology</i> , 2005, 23, 7296-7306.	0.8	123
5	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005, 24, 2461-2473.	2.6	118
6	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003, 102, 1588-1594.	0.6	113
7	An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. <i>BMC Medical Genomics</i> , 2008, 1, 37.	0.7	104
8	Differential repetitive DNA methylation in multiple myeloma molecular subgroups. <i>Carcinogenesis</i> , 2009, 30, 1330-1335.	1.3	99
9	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 3130-3142.	3.2	86
10	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999, 93, 1330-1337.	0.6	80
11	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. <i>Leukemia</i> , 2020, 34, 234-244.	3.3	80
12	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER <sup>+</sup> metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	9.4	77
13	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. <i>BMC Medical Genomics</i> , 2013, 6, 27.	0.7	73
14	Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14). <i>American Journal of Pathology</i> , 2000, 156, 1505-1513.	1.9	72
15	Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 136, 565-573.	1.2	66
16	Molecular spectrum of <i>BRAF</i> , <i>NRAS</i> and <i>KRAS</i> gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. <i>Oncotarget</i> , 2015, 6, 24205-24217.	0.8	65
17	Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 226-238.	1.5	62
18	Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 521-531.	1.5	60

#	ARTICLE	IF	CITATIONS
19	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013, 88, 16-23.	2.0	60
20	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. <i>Clinical Cancer Research</i> , 2013, 19, 5890-5900.	3.2	60
21	Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). <i>British Journal of Haematology</i> , 2001, 114, 362-364.	1.2	59
22	Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 781-793.	1.5	59
23	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. <i>Blood</i> , 1999, 94, 724-732.	0.6	58
24	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2011, 6, 188-194.	1.3	58
25	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015, 6, 17543-17558.	0.8	55
26	Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion. <i>Clinical Cancer Research</i> , 2010, 16, 5641-5653.	3.2	52
27	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014, 165, 629-639.	1.2	52
28	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. <i>Clinical Cancer Research</i> , 2014, 20, 4141-4153.	3.2	52
29	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 146, 44-53.	1.2	50
30	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 3247-3258.	3.2	50
31	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 117-127.	1.5	49
32	CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. <i>Hematological Oncology</i> , 2009, 27, 140-147.	0.8	46
33	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. <i>Oncotarget</i> , 2015, 6, 26129-26141.	0.8	40
34	Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. <i>Oncotarget</i> , 2016, 7, 21353-21361.	0.8	40
35	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. <i>Journal of Pathology</i> , 2005, 206, 337-345.	2.1	39
36	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 612-621.	1.5	38

#	ARTICLE	IF	CITATIONS
37	The Role of New Technologies in Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2019, 9, 321.	1.3	37
38	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e24313.	1.1	36
39	B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 32-36.	2.0	36
40	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. <i>Haematologica</i> , 2007, 92, 56-65.	1.7	34
41	Compendium of <i>FAM46C</i> gene mutations in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2016, 174, 642-645.	1.2	34
42	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors. <i>Clinical Cancer Research</i> , 2012, 18, 1870-1878.	3.2	33
43	Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 261-269.	1.5	31
44	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018, 103, e245-e248.	1.7	29
45	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 24-31.	2.0	27
46	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 726-734.	1.5	24
47	EGFR through STAT3 modulates $\beta$ -tubulin expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. <i>Journal of Cellular Physiology</i> , 2013, 228, 871-878.	2.0	24
48	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158.	0.6	23
49	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	2.9	22
50	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 133, 060118040555003.	1.2	20
51	Molecular and transcriptional characterization of the novel 17p11.2p12 amplicon in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1109-1118.	1.5	20
52	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	2.3	16
53	Repetitive DNA Hypomethylation in Multiple Myeloma. <i>Blood</i> , 2008, 112, 2703-2703.	0.6	16
54	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e402.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 637116.	1.3	15
56	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. <i>PLoS ONE</i> , 2015, 10, e0118801.	1.1	15
57	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€CLL1â€GISL study. <i>American Journal of Hematology</i> , 2014, 89, 743-750.	2.0	14
58	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. <i>Clinical Science</i> , 2020, 134, 1151-1166.	1.8	14
59	The clinical and biological features of a series of immunophenotypic variant of Bâ€CLL. <i>European Journal of Haematology</i> , 2010, 85, 120-129.	1.1	13
60	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	13
61	Global methylation patterns in primary plasma cell leukemia. <i>Leukemia Research</i> , 2018, 73, 95-102.	0.4	13
62	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. <i>Scientific Reports</i> , 2020, 10, 18427.	1.6	13
63	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. <i>Non-coding RNA</i> , 2020, 6, 11.	1.3	11
64	Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. <i>Haematologica</i> , 2005, 90, 1541-8.	1.7	11
65	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544.	2.0	10
66	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 264-273.	1.5	10
67	Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2011, 17, 834-839.	1.9	9
68	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015, 168, 455-459.	1.2	9
69	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. <i>Journal of Pathology</i> , 2003, 200, 596-601.	2.1	8
70	Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. <i>Hematological Oncology</i> , 2007, 25, 6-10.	0.8	8
71	Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia. <i>Histopathology</i> , 2017, 70, 1000-1008.	1.6	8
72	Anagrelide and Mutational Status in Essential Thrombocythemia. <i>BioDrugs</i> , 2016, 30, 219-223.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€œscp>CLL</scp> 1â€œscp>GISL</scp> study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	1.1	7
74	Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,. <i>Blood</i> , 2011, 118, 3890-3890.	0.6	7
75	Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. <i>Clinical Hematology International</i> , 2022, 4, 52-55.	0.7	7
76	Molecular events underlying interleukinâ€œ6 independence in a subclone of the CMAâ€œ03 multiple myeloma cell line. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 154-167.	1.5	6
77	An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. <i>Leukemia Research Reports</i> , 2017, 8, 7-10.	0.2	6
78	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
79	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999, 93, 1330-1337.	0.6	6
80	Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16A-3;q32) chromosomal translocation. <i>British Journal of Haematology</i> , 2004, 126, 437-439.	1.2	5
81	Frequency and clinical relevance of coding and noncoding <i>NOTCH1</i> mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408.	0.8	5
82	LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. <i>Hematological Oncology</i> , 2022, 40, 41-48.	0.8	5
83	Biological and molecular characterization of a rare case of cutaneous Richter syndrome. <i>Hematological Oncology</i> , 2017, 35, 869-874.	0.8	4
84	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010, 34, e217-e218.	0.4	3
85	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3
86	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. <i>Thrombosis Research</i> , 2022, 210, 67-69.	0.8	3
87	Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. <i>Pathology and Oncology Research</i> , 2017, 23, 281-286.	0.9	2
88	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	0.4	1
89	Demystifying the diagnostic criteria of indolent systemic mastocytosis. <i>Hematological Oncology</i> , 2022, 40, 123-125.	0.8	0
90	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. <i>Blood</i> , 2011, 118, 2847-2847.	0.6	0

#	ARTICLE	IF	CITATIONS
91	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1780-1780.	0.6	0
92	Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib. <i>Frontiers in Oncology</i> , 2021, 11, 734025.	1.3	0